Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC)
dc.contributor.author | Latif, Tahir | en_US |
dc.contributor.author | Wood, Laura | en_US |
dc.contributor.author | Connell, Cindy | en_US |
dc.contributor.author | Smith, David C. | en_US |
dc.contributor.author | Vaughn, David J. | en_US |
dc.contributor.author | Lebwohl, David | en_US |
dc.contributor.author | Peereboom, David | en_US |
dc.date.accessioned | 2006-09-11T15:51:13Z | |
dc.date.available | 2006-09-11T15:51:13Z | |
dc.date.issued | 2005-01 | en_US |
dc.identifier.citation | Latif, Tahir; Wood, Laura; Connell, Cindy; Smith, David C.; Vaughn, David; Lebwohl, David; Peereboom, David; (2005). "Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC)." Investigational New Drugs 23(1): 79-84. <http://hdl.handle.net/2027.42/45255> | en_US |
dc.identifier.issn | 0167-6997 | en_US |
dc.identifier.issn | 1573-0646 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/45255 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=15528984&dopt=citation | en_US |
dc.description.abstract | JM-216 is an orally bioavailable platinum compound with activity against many tumor models. The objective of this study was to determine the safety profile and anti-tumor activity of JM-216 in patients with hormone refractory prostate cancer (HRPC) when given orally daily × 5 days. In this open label phase II study JM-216 was administered orally at the dose of 120 mg/m 2 /d for 5 days every 4 weeks. Patients continued on the therapy until evidence of disease progression or intolerable toxicity developed. Dose escalation and de-escalation were allowed according to patient's tolerance. Thirty-nine patients were enrolled onto the study and received a total of 155 courses (median 2, range 1–16) of JM-216. Dose delays (77% of courses) and dose reductions (31% of courses) were common and were mainly due to myelosupression. Treatment was discontinued in 5 patients due to treatment related toxicities. One patient developed myelodysplastic syndrome 11 months after the start of treatment. The most frequent grade III or higher adverse events included thrombocytopenia (54%), neutropenia (52%), anemia (24%) nausea (13%), vomiting (16%) and diarrhea (28%). PSA response was assessed in 32 patients, 10 (26%) had partial response, 14 (36%) had stable disease while PSA progression was seen in 8 (21%) patients. Of 20 (54%) patients with measurable disease two patients had a documented partial response. Although JM-216 had moderate activity in HRPC when given on daily basis for 5 days, it is associated with significant treatment related toxicities in this patient population. | en_US |
dc.format.extent | 66154 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Kluwer Academic Publishers; Springer Science+Business Media | en_US |
dc.subject.other | Medicine & Public Health | en_US |
dc.subject.other | Pharmacology/Toxicology | en_US |
dc.subject.other | Oncology | en_US |
dc.subject.other | Hormone Refractory Prostate Cancer (HRPC) | en_US |
dc.subject.other | JM-216 (BMS-18751, Satraplatin) | en_US |
dc.subject.other | Phase II Open-label Study | en_US |
dc.subject.other | Prostate-specific Antigen (PSA) | en_US |
dc.title | Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC) | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Chemistry | en_US |
dc.subject.hlbsecondlevel | Biological Chemistry | en_US |
dc.subject.hlbsecondlevel | Radiology | en_US |
dc.subject.hlbsecondlevel | Chemical Engineering | en_US |
dc.subject.hlbtoplevel | Science | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.subject.hlbtoplevel | Engineering | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | The University of Michigan, Ann Arbor MI, 481090, Cleveland | en_US |
dc.contributor.affiliationother | Department of Hematology and Medical Oncology, Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland OH, 44195 | en_US |
dc.contributor.affiliationother | Department of Hematology and Medical Oncology, Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland OH, 44195 | en_US |
dc.contributor.affiliationother | University Hospitals of Cleveland, Cleveland OH, 44106 | en_US |
dc.contributor.affiliationother | Abramson Cancer Center at the University of Pennsylvania, Philadelphia PA, 19104 | en_US |
dc.contributor.affiliationother | Novartis Oncology, Florham Park, NJ | en_US |
dc.contributor.affiliationother | Department of Hematology and Medical Oncology, Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland OH, 44195 | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 15528984 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/45255/1/10637_2004_Article_5384229.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1023/B:DRUG.0000047109.76766.84 | en_US |
dc.identifier.source | Investigational New Drugs | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.